3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
19
Paclitaxel
10
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Docetaxel
9
Cyclophosphamide
9
Specimen Handling
8
Cisplatin
8
Gemcitabine
7
Drug Therapy
7
sargramostim
6
Pemetrexed
6
Nivolumab
6
fludarabine
5
aldesleukin
5
Trastuzumab
5
Bevacizumab
5
Taxes
4
Fluorouracil
4
Blood Specimen Collection
4
Amifostine
4
veliparib
3
pegfilgrastim
3
Topotecan
3
Irinotecan
3
IFL protocol
3
Fluorodeoxyglucose F18
3
Etoposide
3
Early Intervention, Educational
3
tariquidar
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
rocakinogene sifuplasmid
×
Gynecologic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled